JD Health posts strong H1 2025 revenue and profit growth

JD Health International Inc. announced its interim results for the six months ended June 30, 2025, reporting a 24.5% year-over-year increase in total revenue to RMB35.3 bn, up from RMB28.3 bn in H1 2024. Product revenue from pharmaceutical and healthcare products grew by 22.7% to RMB29.3 bn, while service revenue surged by 34.4% to RMB6.0 bn. The company's gross profit reached RMB8.9 bn with a gross profit margin of 25.2%.

The company reported a profit for the period of RMB2,591.3 m, compared to RMB2,034.4 m in the prior year. Basic earnings per share increased to RMB0.82 from RMB0.65. Net cash generated from operating activities significantly rose to RMB6.2 bn for the six months ended June 30, 2025, compared to RMB2.2 bn for the same period in 2024.

JD Health's annual active user accounts surpassed 200 m, and the average daily online consultation volume exceeded 500,000 in the first half of 2025. The company continued to expand its omnichannel model, enhancing direct sales, online marketplace, and on-demand retail, while also advancing AI-enhanced service models. As of June 30, 2025, the number of merchants on its marketplace exceeded 150,000.